Described herein, inter alia, are compositions of PCNA modulators and methods for treating or preventing cancer.

Described herein, inter alia, are compositions of PCNA modulators and methods for treating or preventing cancer.

The present invention provides compounds according to Formula I as described herein, and their use for inhibiting the lysine gingipain protease (Kgp) from the bacterium Porphyromonas gingivalis. Also described are gingipain activity probe compounds and methods for assaying gingipain activity are also described, as well as methods for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease.

The present invention provides compounds according to Formula I as described herein, and their use for inhibiting the lysine gingipain protease (Kgp) from the bacterium Porphyromonas gingivalis. Also described are gingipain activity probe compounds and methods for assaying gingipain activity are also described, as well as methods for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease.

It is related to compounds used as autophagy modulators and a method for preparing and using the same, specifically providing a compound of general formula (I), or pharmaceutically acceptable salts thereof, which is a type of autophagy modulators, particularly mammalian ATG8 homologues modulators. ##STR00001##

Small molecule stimulators of steroid receptor coactivator (SRC) family proteins are provided, as well as methods for their use in treating or preventing cancer. Also provided are methods for stimulating SRC family proteins in a cell.

Small molecule stimulators of steroid receptor coactivator (SRC) family proteins are provided, as well as methods for their use in treating or preventing cancer. Also provided are methods for stimulating SRC family proteins in a cell.

A method for the synthesis of specialized pro-resolving mediators, structural isomers thereof and analogs thereof is disclosed herein. The method comprises reacting a compound of the formula (I):

##STR00001## wherein R.sub.1 is alkyl.sub.(C≤12), cycloalkyl.sub.(C≤12), alkenyl.sub.(C≤12), alkylidene.sub.(C≤12), alkynyl.sub.(C≤12), aryl, aralkyl, heteroaryl or heteroaralkyl; and X.sub.1, X.sub.2 and X.sub.3 are each independently hydroxy or OP, wherein P is a hydroxy protecting or hydroxy activating group; with a reducing agent under conditions sufficient to produce a compound of the formula (II):

##STR00002## wherein: R.sub.1, X.sub.1, X.sub.2 and X.sub.3 are as defined above.

Novel protectins, more specifically novel structural isomers and analogs of PD1 and PDX are also disclosed.

A method for the synthesis of specialized pro-resolving mediators, structural isomers thereof and analogs thereof is disclosed herein. The method comprises reacting a compound of the formula (I):

##STR00001## wherein R.sub.1 is alkyl.sub.(C≤12), cycloalkyl.sub.(C≤12), alkenyl.sub.(C≤12), alkylidene.sub.(C≤12), alkynyl.sub.(C≤12), aryl, aralkyl, heteroaryl or heteroaralkyl; and X.sub.1, X.sub.2 and X.sub.3 are each independently hydroxy or OP, wherein P is a hydroxy protecting or hydroxy activating group; with a reducing agent under conditions sufficient to produce a compound of the formula (II):

##STR00002## wherein: R.sub.1, X.sub.1, X.sub.2 and X.sub.3 are as defined above.

Novel protectins, more specifically novel structural isomers and analogs of PD1 and PDX are also disclosed.

Described herein are compounds that are farnesoid X receptor agonists, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with farnesoid X receptor activity.